Tiziana Life Sciences (TLSA) has released an update. Tiziana Life Sciences has reported promising progress in its lead programs targeting neurodegenerative and autoimmune diseases, particularly with its drug Foralumab. Encouraging
Tiziana Life Sciences (TLSA) has released an update. Tiziana Life Sciences has reported promising progress in its lead programs targeting neurodegenerative and autoimmune diseases, particularly with its drug Foralumab. Encouraging
Tiziana Life Sciences (TLSA) has released an update. Tiziana Life Sciences has been awarded a $4 million NIH grant to fund research on its pioneering intranasal anti-CD3 monoclonal antibody foralumab
Tiziana Life Sciences announced the National Institutes of Health, NIH, National Institute on Aging have awarded a $4 Million grant to Dr. Howard Weiner as principal investigator at Brigham and
Tiziana Life Sciences (TLSA) has released an update. Tiziana Life Sciences has announced Ivor Elrifi as its new CEO, a seasoned expert in intellectual property and business development within the
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief